Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer
Open accessThe DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
Taxanes are an established option in the standard treatment paradigm for patients with metastatic breast cancer (MBC). Neuropathy is a common, dose-limiting side effect of taxane therapy that is often managed by dose reductions and delays. The severity, time to onset, and improvement in neuropathy are important considerations for patient management and vary among currently approved taxanes. The rate of grade ≥3 neuropathy with taxanes has been shown to be dose and schedule dependent; however, time to improvement to grade ≤1 is typically shorter for nab-paclitaxel than for other taxanes in patients with MBC. Many tools for assessing patient-reported neuropathy exist. Because MBC is incurable and patient quality of life must be critically considered when making treatment decisions, there is a need for more prospective trials to assess patient-reported neuropathy. Validated predictors of taxane-related neuropathy may play an important role in treatment decisions in the future. This review will focus on the toxicity profile (i.e., neuropathy) of each of the taxanes used in the treatment of MBC, will provide updates on tools used for the assessment of neuropathy, and will highlight newly discovered predictors of taxane-related neuropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other common symptoms among cancer patients (e.g., nausea, neuropathy, swelling of arms and legs, hot flashes, cognitive problems) have received less attention in the MBC literature [6, 12–14].”
From Symptom experiences in metastatic breast cancer patients: relationships to activity engagement, value-based living, and psychological inflexibility (2017) · cites this paper as [13]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081 · cited 1×
“[85] Metastatic or locally advanced, previously treated (346) Paclitaxel 90 mg/m(2) weekly for 3 of 4 weeks NR 17 <1”
BackgroundGradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153 · cited 1×
“[17] Metastatic, previously treated (229) nab-Paclitaxel 260 mg/m(2) q3w NR 10 0”
Dyck, P. J., Kratz, K. M., Karnes, J. L., Litchy, W. J., Klein, R., Pach, J. M., Wilson, D. M., O'Brien, P. C., & Melton, L. J. (1993) · Neurology · doi:10.1212/wnl.43.4.817 · Cited by 1,482
Smith, E. M. L., Pang, H., Cirrincione, C., Fleishman, S., Paskett, E. D., Ahles, T., Bressler, L. R., Fadul, C. E., Knox, C., Le-Lindqwister, N., et al. (2013) · JAMA · doi:10.1001/jama.2013.2813 · Cited by 1,014
Chemotherapy-induced peripheral neuropathy
Quasthoff, S., & Hartung, H. P. (2002) · Journal of Neurology · doi:10.1007/pl00007853 · Cited by 966
Miles, D. W., Chan, A., Dirix, L. Y., Cortés, J., Pivot, X., Tomczak, P., Delozier, T., Sohn, J. H., Provencher, L., Puglisi, F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6457 · Cited by 897 · cited 1×
“[84] Metastatic or locally advanced, previously treated (231) Docetaxel 100 mg/m(2) q3w NR 2 (grade 3 or higher)”
BackgroundAbbott, C. A., Malik, R. A., van Ross, E. R. E., Kulkarni, J., & Boulton, A. J. M. (2011) · Diabetes Care · doi:10.2337/dc11-1108 · Cited by 868
Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I., Okamoto, I., Hon, J. K., Hirsh, V., Bhar, P., Zhang, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5848 · Cited by 756 · cited 1×
“With respect to taxane-based therapy, in an exploratory analysis of a phase III trial in patients with advanced non-small cell lung cancer, those with diabetes who were treated with nab-paclitaxel plus carboplatin had a 4 % higher rate of grade ≥3 peripheral neuropathy (7 %) than did the intent-to-treat population (3…”
Seidman, A. D., Berry, D., Cirrincione, C., Harris, L., Muss, H., Marcom, P. K., Gipson, G., Burstein, H., Lake, D., Shapiro, C. L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6699 · Cited by 594 · cited 2×
“[29] Metastatic, previously treated (225) Paclitaxel 175 mg/m(2) q3w 21 12 0”
BackgroundPharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy
ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 591
Research works printed but not linked: 1
- Hirsh V, Owen SP, Ko A, Renschler MF, Socinski MA (2013) nab-Paclitaxel in combination with carboplatin as first-line therapy in diabetic patients with advanced non-small cell lung cancer (NSCLC). In: 15th World conference on lung cancer, poster P1 10-044
Cited by
Items 101–158 of 158
EarlyR signature predicts response to neoadjuvant chemotherapy in breast cancer
Buechler, S. A., Gökmen‐Polar, Y., & Badve, S. (2018) · The Breast · doi:10.1016/j.breast.2018.11.006 · Cited by 7
Chen, J., Chu, X., Wu, Y., Su, L., Wang, M., Zhao, X., Wei, X., Xia, G., Xia, H., Lin, S., et al. (2026) · Neoplasia · doi:10.1016/j.neo.2026.101291 · Cited by 5
“…damage is frequently amplified by mitochondrial dysfunction: cisplatin-induced mtDNA damage impairs respiratory chain function [73], while taxane-mediated microtubule disruption blocks mitochondrial transport to dendritic spines, creating localized mitochondrial energy deficits at synapses [74,75].”
Dai, M., Chao, T., Chiu, C., Lu, Y., Shiah, H., Jackson, C., Hung, N. A., Zhi, J., Cutler, D. L., Kwan, R., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231183680 · Cited by 5
“Patients The major inclusion criteria were as follows: (1) patients with advanced breast cancer for whom IV paclitaxel 80 mg/m2 weekly monotherapy was recommended by their oncologist; (2) measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.”
MethodGoula, I., Alikari, V., Charalampous, G., Tzavella, F., Zyga, S., Tsironi, M., & Theofilou, P. (2020) · Health Psychology Report · doi:10.5114/hpr.2020.93757 · Cited by 5
“Studies focusing on adjuvant therapies have reported negative effects on body image, psychosocial well-being, physical function (Turgay, Khorshid, & Eser, 2008), social function and hence the QoL during adjuvant chemotherapy (Rivera & Cianfrocca, 2015).”
BackgroundMacular Cystoid Edema Induced by Nab-Paclitaxel
Pereira, S. A., Vale, C., Moreira, J., & Sampaio, F. (2021) · Acta Médica Portuguesa · doi:10.20344/amp.13421 · Cited by 5
Impact of Chemotherapy-Induced Peripheral Neuropathy on the Quality of Life in Cancer Patients
Novak, M. (2022) · Acta Clinica Croatica · doi:10.20471/acc.2022.61.01.07 · Cited by 4
Dekamin, S., Ghasemi, M., Dehpour, A. R., Ghazi‐Khansari, M., & Shafaroodi, H. (2024) · Neurochemical Research · doi:10.1007/s11064-023-04088-3 · Cited by 4
“Neuropathy can manifest with numbness, tingling, pain, and weakness, predominantly in the hands and feet [1, 9, 10].”
Potthoff, K., Stötzer, O. J., Söling, U., Hansen, R., Harde, J., Dille, S., Nusch, A., & Marschner, N. W. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.11.003 · Cited by 4
Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report
Gluz, O., Kolberg‐Liedtke, C., Marmé, F., & Thill, M. (2020) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1126-4247 · Cited by 4
“in adult patients in whom the first-line treatment of metastatic disease has failed and for whom standard anthracyclinecontaining therapy is not indicated (in HER2-pos in combination with antiHER2 therapy) Alopecia,myelosuppression, peripheral polyneuropathy in 9–22% of cases (grade 3–4) [5] No premedication required…”
BackgroundRattanakrong, N., Siriphorn, A., & Boonyong, S. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-022-07181-5 · Cited by 4
“However, a common adverse effect of taxanebased chemotherapy treatment is taxane-induced peripheral neuropathy (TIPN) symptoms [6].”
BackgroundReinhorn, D. J., Kuchuk, I., Shochat, T., Nisenbaum, B., Sulkes, A., Hendler, D., Rotem, O., Tsoref, D., Olitzky, O., Goldvaser, H., et al. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06198-4 · Cited by 4
“While combination with a taxane is considered standard of care in this setting [4, 5], it has considerable toxicity which can have a profound adverse impact on quality of life [11, 12].”
BackgroundKarakoç, M. D., Özmen, Ö., ZENGİN, M. N., & Çiftçi, O. (2025) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x2025e14602 · Cited by 4
“Various antineoplastic agents are associated with neurotoxicity and chemotherapy-induced PN, with docetaxel (DTX) standing out as one of the most likely to cause these side effects (4).”
The role of bacteria in the treatment of cancer: A comprehensive review
Khadem, E., Nafari, A., Safarzadeh, A., Jozaei, R. F., Almasian, M., & Elyasi, H. (2020) · Plant Biotechnology Persa · doi:10.29252/pbp.2.1.26 · Cited by 3
Talaee, N., Ebrahimpour, S., Sfandbod, M., Majedi, H., Kohneloo, A. J., Gholami, K., & Jahangard‐Rafsanjani, Z. (2021) · Pharmaceutical Sciences · doi:10.34172/ps.2021.81 · Cited by 5
“(African-American), comorbid factors such as diabetes, and obesity may increase the risk of paclitaxel-induced neuropathy.(7) The incidence of acute pain is reported to be up to 70%,(8,9) and is seen in breast cancer patients more than others.”
BackgroundLiu, Y., Song, G., Di, L., Jiang, H., Ran, R., Zhang, R., Zhang, Y., & Li, H. (2023) · The Oncologist · doi:10.1093/oncolo/oyad288 · Cited by 3
Lin, H.-F., Tseng, C.-Y., Mündel, T., Lin, Y.-Y., Lin, C., Chen, C., & Liao, Y. (2021) · Biology · doi:10.3390/biology10090910 · Cited by 7
“The side effects of paclitaxel and docetaxel, which are the most widely used taxanes for treating breast cancer, include peripheral nerve damage [11,12].”
BackgroundA Palliative Care Clinic's Experience with Medication Adherence to Neuropathic Pain Medications
Dayer, L. E., Harrington, S. E., & Martin, B. C. (2016) · Journal of Palliative Medicine · doi:10.1089/jpm.2015.0230 · Cited by 3
RetractedFukada, I., Ito, Y., Kobayashi, K., Shibayama, T., Takahashi, S., Horii, R., Akiyama, F., Iwase, T., & Ohno, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184322 · Cited by 3
Taxane‑induced polyneuropathy - current possibilities of prediction and management
Jablonická, M., Žideková, L., & Mladosievičová, B. (2021) · Vnitřní lékařství · doi:10.36290/vnl.2021.014 · Cited by 3
Cui, M., Guo, Y., Lu, Z., Huang, Z., Guo, X., & Wang, Y. (2025) · BMC Nursing · doi:10.1186/s12912-025-04157-8 · Cited by 2
“The optimal cut-off point on the ROC curve (i.e., the point maximizing diagnostic performance) was selected as the scale’s diagnostic threshold [6].”
Kruse, A. M., Veld, E. A. H. I. ’., van Grotel, M., Amant, F. C., van Tinteren, H., van den Heuvel‐Eibrink, M. M., & Verwaaijen, E. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103738 · Cited by 2
“24 These agents are known for their neurotoxic side effects, including peripheral neuropathy and motor impairment, in both adults and children.”
Rattanakrong, N., Siriphorn, A., & Boonyong, S. (2022) · Physiotherapy Theory and Practice · doi:10.1080/09593985.2022.2139654 · Cited by 2
“Generally, TIPN symptoms such as numbness, tingling, muscle cramps, and muscle weakness emerge at the tips of the toes or fingers (Dougherty et al., 2004; Freilich et al., 1996).”
BackgroundInfluentialNielsen, A., Marstrand, S. D., Marina, D., Andersson, M., Jensen, L. T., Buch‐Larsen, K., & Schwarz, P. (2025) · Cancer Investigation · doi:10.1080/07357907.2025.2510996 · Cited by 2
“Items 19 and 20 represents a motor and an autonomic item regarding the use of pedals in a car and maintaining an erection.”
Shahpar, S., Mhatre, P. V., & Oza, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35955-9.00083-0 · Cited by 1
Riera, P., Apellániz, M. V., & Salazar, J. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.09.004 · Cited by 2
Mitosis Inhibitors and Medicinal Plants: Neurotoxicity and Neuroprotection
Özenver, N., & Efferth, T. (2021) · Springer eBooks · doi:10.1007/978-981-33-4141-8_1 · Cited by 2
Impact of Chemotherapy and Radiation on Breast Sensation After Immediate Reconstruction
Qin, N., Gundlach, C., Kochheiser, M., Black, G. G., Freitag, R. E., Vaeth, A. M., Chen, Y., Zhang, A., Arbuiso, S., Romero, E., et al. (2025) · Annals of Plastic Surgery · doi:10.1097/sap.0000000000004289 · Cited by 1
Kassem, A. B., Ahmed, A. A., El‑Bassiouny, N. A., Omran, G. A., Kamel, M. M., Bastawisy, A. E., & Abuelsoud, N. N. (2025) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-025-00827-1 · Cited by 1
“Despite their impressive effectiveness in improving patient outcomes, subjective well-being and tolerability to chemotherapy protocols are greatly affected by taxanes adverse drug reactions (ADRs) [6].”
Moretti, N. R., Moreira, B. D. M., Braz, I. P., Barretto, I. C. D. O., Chiba, A. L. A. Z., Dominato, A. A. G., & de Moraes, F. C. A. (2025) · Biomarkers · doi:10.1080/1354750x.2025.2522892 · Cited by 2
“…to peripheral axons, leading to phenotypic correlates of an axonal degeneration pattern, with more pronounced impairment in large myelinated aβ fibres (Rivera and cianfrocca 2015). therefore, microtubule stabilization results in the loss of axonal transport, promoting axonal degeneration or…”
Wolbink, J. N., van Bodegom‐Vos, L., Blok, E. J., & Portielje, J. E. A. (2025) · Ageing and Cancer Research & Treatment · doi:10.70401/acrt.2025.0001 · Cited by 1
Did axons evolve by activating cytokinesis during interphase? A hypothesis on the origin of neurons
Miller, K. E., Oprea, F., Alam, S., Grodsky, A., & Craig, E. M. (2025) · Molecular Biology of the Cell · doi:10.1091/mbc.e24-12-0585 · Cited by 1
“In parallel, an evolutionary link between cell division and neurons may explain why therapies designed to treat cancer can induce neuropathy (Gornstein and Schwarz, 2014; Rivera and Cianfrocca, 2015).”
Beheshtirouy, S., Nikniaz, Z., Ghaffary, S., Jaberi, R., & Shaseb, E. (2025) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552251405216 · Cited by 1
“6,7 More recent evidence has challenged this assumption, suggesting that TIPN is mostly attributed to the taxane molecules rather than the components of the formulation.”
Antibody-drug conjugates: new drugs – new toxicities
Wong, M. H., Rahman, N., & Lustberg, M. B. (2026) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001214 · Cited by 2
Levard, R., Mesnilgrante, O., Bon, P. L., Evenden, P., L’ORPHELIN, J. M., Lebaube, S., Villemin, M., Delarue, E., Dumont, A., Basti, S., et al. (2026) · Supportive Care in Cancer · doi:10.1007/s00520-026-11108-9 · Cited by 1
Paralytic ileus due to a novel anticancer drug, nab-paclitaxel: A case report
Jiao, X., Luo, X., Qin, W., Yuan, L., & Zang, Y. (2016) · Molecular and Clinical Oncology · doi:10.3892/mco.2016.782 · Cited by 1
Genetic determinants of taxane-induced peripheral neuropathy
Mladosievičová, B., Jablonická, M., TATAYOVA, L., & Bernadic, M. (2024) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.4149/bll_2024_31 · Cited by 1
Martins, D., Acha, B. T., Cavalcante, M. L. D. S., Pereira, S., Viana, A., Neto, F. R. P., Mendes, P., Dittz, D., Oliveira, F. D. A., Ventura, T. J. T. V., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18020256 · Cited by 1
“…that can present themselves during treatment and persist as long-term sequelae in many cancer survivors, such as cancer-related fatigue (CRF), chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-related cognitive impairment (CRCI), and ovarian failure or infertility [10,11].”
Musculoskeletal Effects of Antineoplastic Agents
Sutton, K. M., Sanft, T. B., Knobf, M. T., & Ibe, I. K. (2019) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/jaaos-d-17-00713 · Cited by 1
Terzi, H., Mustafa, E., Ergül, M., Ahmet, A., & Mehmet, S. (2019) · Indian Journal of Pharmaceutical Sciences · doi:10.36468/pharmaceutical-sciences.616 · Cited by 1
“There are different options to overcome this problem, including combinatory therapy[10,11].”
Background张, 瑾. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.127919 · Cited by 1
Galletti, G., & Giannakakou, P. (2023) · Wiley eBooks · doi:10.1002/9781119000822.hfcm061.pub2 · Cited by 1
Neurological Complications of Breast Cancer and Its Treatment
Rhun, É. L., Taillibert, S., & Chamberlain, M. C. (2017) · Springer eBooks · doi:10.1007/978-3-319-57901-6_23
Exercise influence on taxane side effects in women with breast cancer
Bland, K. A. (2017) · cIRcle (University of British Columbia) · doi:10.14288/1.0357131 · Cited by 1
“non-dividing cells, peripheral nerves may be more vulnerable to neurotoxic damage due to their extended axonal length and permeability of the blood nerve barrier.(46) Biopsies of nerves treated with paclitaxel have shown axonal degeneration, secondary demyelination and in severe instances, complete nerve fibre loss.”
BackgroundEllithy, M., Elwakil, L., Schaalan, M. F., & Hossamy, Y. E. (2018) · Research in Oncology · doi:10.21608/resoncol.2018.3375.1055
PHARMACOGENOMICS IN THE EMIRATI POPULATION: APPLICATIONS IN CARDIOVASCULAR DISEASES AND ONCOLOGY
Mahairi, A., & Nizar, Z. (2020) · Cited by 1
Rattanakrong, N., Siriphorn, A., & Boonyong, S. (2022) · Research Square · doi:10.21203/rs.3.rs-1291231/v1
Riera, P., Apellániz, M. V., & Salazar, J. (2018) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2017.12.023
Mahmood, A., & Alawad, A. S. (2023) · Iraqi postgraduate Medical Journal · doi:10.52573/ipmj.2023.180583
A Prospective Observational Study on Neurotoxicity of Chemotherapy - A Critical Analysis
Hussaini, S. Z. K., Jilla, S., Gumdal, V., Peddapalegani, P., Kalidindi, D., Kashadatla, R., Chaitanya, K., & Kommu, K. (2024) · Journal of Radiology and Oncology · doi:10.29328/journal.jro.1001061
O’Meara, T. A., & Tarantino, P. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02717
Chemotherapy: A powerful weapon in ovarian cancer treatment
Shah, S., Yasir, M., Tripathi, A. S., Mohapatra, L., Maurya, R. K., Hasan, T., & Prajapati, B. G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33536-5.00005-5
Attenuating Neurotoxicity Through Fecal Microbiota Transplant: Mechanisms and Therapeutic Potential
Younis, N. K., Alfarttoosi, K. H., Sanghvi, G. V., Roopashree, R., Kashyap, A., Krithiga, T., Taher, W. M., Alwan, M., Jawad, M. J., & Al-Nuaimi, A. M. A. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05415-1
Teran-Wodzinski, P. C., Haladay, D. E., Vu, T., Ji, M., Coury, J., Adams, A., Schwab, L., & Visovsky, C. (2022) · Figshare · doi:10.6084/m9.figshare.19669973
Teran-Wodzinski, P. C., Haladay, D. E., Vu, T., Ji, M., Coury, J., Adams, A., Schwab, L., & Visovsky, C. (2022) · Figshare · doi:10.6084/m9.figshare.19669976
Claes, M., Lodewijckx, J., Robijns, J., Hermans, S., Peeters, P., & Mebis, J. (2026) · Lasers in Medical Science · doi:10.1007/s10103-026-04852-1 · Cited by 1
“As a result, a reduction of the chemotherapy dosage or withdrawal of chemotherapy is often necessary to man-agetheseverityofCIPN,whichcouldaffectthetreatment outcome [9–12].”
Hawas, Y., Fauomi, W., Qutob, I. A., Alzu’bi, M., Rezk, N., Hamza, G., ElBadrawy, F., Abdelnaeem, A. M., Elghareeb, H., Arrabyee, M. R., et al. (2026) · Discover Oncology · doi:10.1007/s12672-026-05434-x
“Taxane-related CIPN affects 30-60% of treated patients [35, 36], but is typically sensory-predominant, length-dependent and symmetric [37].”
Metadata
- Authors
- Rivera, E., & Cianfrocca, M.
- Affiliations
- Banner MD Anderson Cancer Center (US)
- Corresponding author
- Rivera, Edgardo
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2015-01-18
- Volume
- 75
- Issue
- 4
- Pages
- 659-670
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- PMC
- PMC4365177
- OpenAlex
- W2061239263
- Cited by
- 159
- References
- 89
- Citations by year
- 2026: 6 · 2025: 16 · 2024: 11 · 2023: 14 · 2022: 19 · 2021: 15 · 2020: 19 · 2019: 7 · 2018: 14 · 2017: 16 · 2016: 14 · 2015: 8
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Cancer Chemotherapy and Pharmacology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Celgene
- Topics
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
- Health Sciences › Medicine › Oncology › Cancer survivorship and care
- Keywords
- taxanes, neuropathy, metastatic breast cancer, nab-paclitaxel, paclitaxel, docetaxel, chemotherapy toxicity, dose-limiting toxicity, patient-reported outcomes, quality of life
- MeSH terms
- Antineoplastic Agents, Breast Neoplasms, Clinical Trials as Topic, Drug Administration Schedule, Female, Humans, Neoplasm Metastasis, Neuralgia, Taxoids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.